, whose cancer therapy Trodelvy is FDA-approved as a third-line treatment for an aggressive type of breast cancer called Metastatic Triple-Negative Breast Cancer, could be announced on Monday if not sooner, the Journal said, citing people familiar with the matter.
Discussions between Gilead and Immunomedics were initially centred around a partnership before shifting to a full-fledged takeover negotiation, the Journal added. Shares of Immunomedics, which last month reported positive data from a late-stage confirmatory study for Trodelvy, have nearly doubled this year, giving the company a valuation of close to $10 billion.Expanding oncology portfolio
An acquisition of Immunomedics would add to several deals Gilead inked this year with the aim of expanding its oncology portfolio. It bought a 49.9 percent stake in cancer drug developer Pionyr Immunotherapeutics in June for $275 million, just months after paying $4.9 billion for Forty Seven Inc, maker of an experimental treatment that targets blood cancer.
Macron: No Talent Macron: Racist Macron: a threat to NATO Makron: Colonial governor Macron: Spoiled Macron: Ignorant Macron: France's misfortune Macron: Supporter of putschists and terrorists
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
Business Business Latest News, Business Business Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Gilead nears deal to buy Immunomedics for more than $20 billion, WSJ reportsGilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday. Isn’t gilead the town/state or what ever in handmaids tale? Under his 👁
Source: Reuters - 🏆 2. / 97 Read more »
Gilead nears deal to buy Immunomedics for more than $20 billion, WSJ reportsGilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday. Under his eye
Source: Reuters - 🏆 2. / 97 Read more »
Gilead nears deal to buy Immunomedics for more than $20 billion, WSJ reportsGilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday. Under his eye
Source: Reuters - 🏆 2. / 97 Read more »
Gilead nears deal to buy Immunomedics for more than $20 billion, WSJ reportsGilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead's portfolio of cancer treatments, the Wall Street Journal reported on Saturday. Isn’t gilead the town/state or what ever in handmaids tale? Under his 👁
Source: Reuters - 🏆 2. / 97 Read more »